Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1859432 | 0.83 | LTA4H (0.52) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL8452874 | 0.83 | LTA4H (0.56) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL9856113 | 0.77 | LTA4H (0.63) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL10422293 | 0.76 | KCNA3 (0.50) | LTA4HLMNACYP2C19HDAC6DRD2 | |
| SCHEMBL6059624 | 0.76 | ESR2 (0.56) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL1923910 | 0.74 | LTA4H (0.54) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL17676808 | 0.74 | IDO1 (0.50) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL10458362 | 0.74 | APP (0.65) | APPLTA4HESR1ESR2NR5A1 | |
| SCHEMBL28204950 | 0.74 | LTA4H (0.44) | APPLTA4HLMNACYP1A2PTGS1 | |
| SCHEMBL28903276 | 0.73 | APP (0.58) | APPLTA4HLMNACYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487080-B2 | Fluorine-labeled compounds | GENERAL ELECTRIC COMPANY (US) | 2013-07-16 | — | — | US | disclosed |
| US-8124725-B2 | PDGF-Rβ binders | GENERAL ELECTRIC COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110160430-A1 | FLUORINE-LABELED COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2011-06-30 | — | — | US | disclosed |
| US-7902332-B2 | Reacting thiol-reactive terminus of linker with a polypeptide and fluorine-substituted aldehyde | GENERAL ELECTRIC COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090191124-A1 | PDGF-RBeta BINDERS | GENERAL ELECTRIC COMPANY (US) | 2009-07-30 | — | — | US | disclosed |
| US-20080139787-A1 | Fluorine-labeled compounds | GENERAL ELECTRIC COMPANY | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139787-A1 | Fluorine-labeled compounds | PFAS, DHFR, PAICS | APP 2352/4885LTA4H 3270/4885LMNA 3929/4885 |
| US-20110160430-A1 | FLUORINE-LABELED COMPOUNDS | PFAS, DHFR, PAICS | APP 2352/4885LTA4H 3270/4885LMNA 3929/4885 |
| US-20090191124-A1 | PDGF-RBeta BINDERS | PDGFRB, PDGFA, PDGFRA | APP 2458/4885LTA4H 4282/4885LMNA 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.